


## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

### Listing of Claims:

1 - 58 (Cancelled)

59. (Currently Amended) A compound of Formula (II), or a pharmaceutically acceptable salt thereof;



II

wherein:

A-B is:


- (a) N-C;
- (b) C-N; or
- (c) N-N;

when sides *d* and *f* are double bonds, and sides *e* and *g* are single bonds,  
-X²-Y²-Z²- is:

- (a) =CR⁴-CR⁴¹=CR⁵-;
- (b) =N-CR⁴=CR⁴¹-;
- (c) =N-CR⁴=N-;
- (d) =CR⁴-N=CR⁴¹-;
- (e) =CR⁴-N=N-;
- (f) =N-N=CR⁴-;
- (g) =N-N=N-;
- (h) (b) =CR⁴-CR⁵=N-; or
- (i) (c) =CR²'-CR⁵=N-;


$R^2$  and  $R^{2'}$ , as defined herein taken together are:

(a)



or

(b)



or  $R^{2'}$  and  $R^5$ , as defined herein, taken together with the carbon atoms to which they are attached are a cycloalkyl group or a heterocyclic ring;

$R^{97}$  is:

- (a) hydrogen;
- (b) alkylthio;
- (c) alkylsulfinyl;
- (d) alkylsulfonyl;
- (e) cyano;
- (f) carboxyl;
- (g) amino;
- (h) lower alkyl;
- (i) haloalkyl;
- (j) hydroxy;
- (k) alkoxy;
- (l) haloalkoxy;
- (m) alkylarylalkylamino;

- (n) aminoalkyl;
- (o) aminoaryl;
- (p) sulfonamido;
- (q) alkylsulfonamido;
- (r) arylsulfonamido;
- (s) heterocyclic ring;
- (t) hydroxyalkyl; or
- (u) nitro;

a is an integer from 1 to 3;

when sides *e* and *g* are double bonds, and sides *d* and *f* are single bonds,

~~-X<sup>2</sup>-Y<sup>2</sup>-Z<sup>2</sup>-~~ is:

- ~~(a) -CR<sup>4</sup>=N-N=;~~
- ~~(b) -N=N-CR<sup>4</sup>=;~~
- ~~(c) -CR<sup>4</sup>=N-CR<sup>4</sup>=;~~
- ~~(d) -N=CR<sup>4</sup>-N=;~~
- ~~(e) -CR<sup>4</sup>=CR<sup>4</sup>-N=;~~
- ~~(f) (a) -N=CR<sup>4</sup>-CR<sup>5</sup>=; or~~
- ~~(g) (b) -CR<sup>4</sup>=CR<sup>5</sup>-CR<sup>5</sup>=; or~~
- ~~(h) -N=N-N=;~~

~~when side *g* is a double bond, and sides *d*, *e* and *f* are single bonds,~~

~~-X<sup>2</sup>-Y<sup>2</sup>-Z<sup>2</sup>-~~ is:

- ~~(a) -C(O)-O-CR<sup>4</sup>=;~~
- ~~(b) -C(O)-NR<sup>3</sup>-CR<sup>4</sup>=;~~
- ~~(c) -C(O)-S-CR<sup>4</sup>=; or~~
- ~~(d) -C(H)R<sup>4</sup>-C(OH)R<sup>5</sup>-N=;~~

~~when sides *d* is a double bond, and sides *e*, *f* and *g* are single bonds,~~


~~-X<sup>2</sup>-Y<sup>2</sup>-Z<sup>2</sup>-~~ is:

- ~~(a) =CR<sup>4</sup>-O-C(O)-;~~
- ~~(b) =CR<sup>4</sup>-NR<sup>3</sup>-C(O)-;~~




~~when sides  $f$  is a double bond, and sides  $d$ ,  $e$  and  $g$  are single bonds,~~

~~$\text{X}^2 - \text{Y}^2 - \text{Z}^2$  is:~~




~~when sides  $e$  is a double bond, and sides  $d$ ,  $f$  and  $g$  are single bonds,~~

~~$\text{X}^2 - \text{Y}^2 - \text{Z}^2$  is:~~






~~when sides  $d$ ,  $e$ ,  $f$  and  $g$  are single bonds,~~

~~$\text{X}^2 - \text{Y}^2 - \text{Z}^2$  is:~~



$\text{R}^1$  is:



$\text{R}^{1'}$  at each occurrence is independently:

(a) hydrogen;

(b) halogen;

(c) methyl; or

(d)  $\text{CH}_2\text{OH}$ ;

$\text{R}^2$  is:

(a) lower alkyl;

(b) cycloalkyl;

(c) mono-, di- or tri-substituted phenyl or naphthyl, wherein the substituents are each independently:

(1) hydrogen;

(2) halo;

(3) alkoxy;

(4) alkylthio;

(5) CN;

(6) haloalkyl, preferably  $\text{CF}_3$ ;

(7) lower alkyl;

(8)  $\text{N}_3$ ;

(9)  $-\text{CO}_2\text{D}^1$ ;

(10)  $-\text{CO}_2$ -lower alkyl;

(11)  $-(\text{C}(\text{R}^5)(\text{R}^6))_z-\text{OD}^1$ ;

(12)  $-(\text{C}(\text{R}^5)(\text{R}^6))_z-\text{O}$ -lower alkyl;

(13) lower alkyl- $\text{CO}_2-\text{R}^5$ ;

(14)  $-\text{OD}^1$ ;

(15) haloalkoxy;

(16) amino;

(17) nitro;

(18) alkylsulfinyl; or

(19) heteroaryl;

(d) mono-, di- or tri-substituted heteroaryl, wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is S, O, or N, and, optionally, 1, 2, or 3 additional N atoms; or the heteroaryl is a monocyclic ring of 6 atoms, said ring having one

heteroatom which is N, and, optionally, 1, 2, 3, or 4 additional N atoms; wherein the substituents are each independently:

- (1) hydrogen;
- (2) halo;
- (3) lower alkyl;
- (4) alkoxy;
- (5) alkylthio;
- (6) CN;
- (7) haloalkyl, preferably CF<sub>3</sub>;
- (8) N<sub>3</sub>;
- (9) -C(R<sup>5</sup>)(R<sup>6</sup>)-OD<sup>1</sup>;
- (10) -C(R<sup>5</sup>)(R<sup>6</sup>)-O-lower alkyl; or
- (11) alkylsulfinyl;

(e) benzoheteroaryl which includes the benzo fused analogs of (d);

(f) -NR<sup>10</sup> R<sup>11</sup>;

(g) -SR<sup>11</sup>;

(h) -OR<sup>11</sup>;

(i) -R<sup>11</sup>;

(j) alkenyl;

(k) alkynyl;

(l) unsubstituted, mono-, di-, tri- or tetra-substituted cycloalkenyl, wherein the substituents are each independently:

- (1) halo;
- (2) alkoxy;
- (3) alkylthio;
- (4) CN;
- (5) haloalkyl, preferably CF<sub>3</sub>;
- (6) lower alkyl;
- (7) N<sub>3</sub>;

- (8)  $-\text{CO}_2\text{D}^1$ ;
- (9)  $-\text{CO}_2$ -lower alkyl;
- (10)  $-\text{C}(\text{R}^{12})(\text{R}^{13})-\text{OD}^1$ ;
- (11)  $-\text{C}(\text{R}^{12})(\text{R}^{13})-\text{O}$ -lower alkyl;
- (12) lower alkyl- $\text{CO}_2\text{R}^{12}$ ;
- (13) benzyloxy;
- (14)  $-\text{O}$ -(lower alkyl)- $\text{CO}_2\text{R}^{12}$ ;
- (15)  $-\text{O}$ -(lower alkyl)- $\text{NR}^{12}\text{R}^{13}$ ; or
- (16) alkylsulfinyl;

(m) mono-, di-, tri- or tetra-substituted heterocycloalkyl group of 5, 6 or 7 members, or a benzoheterocycle, wherein said heterocycloalkyl or benzoheterocycle contains 1 or 2 heteroatoms selected from O, S, or N and, optionally, contains a carbonyl group or a sulfonyl group, and wherein said substituents are each independently:

- (1) halo;
- (2) lower alkyl;
- (3) alkoxy;
- (4) alkylthio;
- (5) CN;
- (6) haloalkyl, preferably  $\text{CF}_3$ ;
- (7)  $\text{N}_3$ ;
- (8)  $-\text{C}(\text{R}^{12})(\text{R}^{13})-\text{OD}^1$ ;
- (9)  $-\text{C}(\text{R}^{12})(\text{R}^{13})-\text{O}$ -lower alkyl; or
- (10) alkylsulfinyl;

(n) styryl, mono or di-substituted styryl, wherein the substituent are each independently:

- (1) halo;
- (2) alkoxy;
- (3) alkylthio;
- (4) CN;

- (5) haloalkyl, preferably  $\text{CF}_3$ ;
- (6) lower alkyl;
- (7)  $\text{N}_3$ ;
- (8)  $-\text{CO}_2\text{D}^1$ ;
- (9)  $-\text{CO}_2$ -lower alkyl;
- (10)  $-\text{C}(\text{R}^{12})(\text{R}^{13})-\text{OD}^1$ ;
- (11)  $-\text{C}(\text{R}^{12})(\text{R}^{13})-\text{O}$ -lower alkyl;
- (12) lower alkyl- $\text{CO}_2-\text{R}^{12}$  ;
- (13) benzyloxy;
- (14)  $-\text{O}$ -(lower alkyl)- $\text{CO}_2\text{R}^{12}$ ; or
- (15)  $-\text{O}$ -(lower alkyl)- $\text{NR}^{12}\text{R}^{13}$  ;

(o) phenylacetylene, mono- or di-substituted phenylacetylene, wherein the substituents are each independently:

- (1) halo;
- (2) alkoxy;
- (3) alkylthio;
- (4)  $\text{CN}$ ;
- (5) haloalkyl, preferably  $\text{CF}_3$ ;
- (6) lower alkyl;
- (7)  $\text{N}_3$ ;
- (8)  $-\text{CO}_2\text{D}^1$ ;
- (9)  $-\text{CO}_2$ -lower alkyl;
- (10)  $-\text{C}(\text{R}^{12})(\text{R}^{13})-\text{OD}^1$ ;
- (11)  $-\text{C}(\text{R}^{12})(\text{R}^{13})-\text{O}$ -lower alkyl;
- (12) lower alkyl- $\text{CO}_2-\text{R}^{12}$ ;
- (13) benzyloxy;
- (14)  $-\text{O}$ -(lower alkyl)- $\text{CO}_2\text{R}^{12}$ ; or
- (15)  $-\text{O}$ -(lower alkyl)- $\text{NR}^{12}\text{R}^{13}$ ;

(p) fluoroalkenyl;



(q) mono- or di-substituted bicyclic heteroaryl of 8, 9 or 10 members, containing 2, 3, 4 or 5 heteroatoms, wherein at least one heteroatom resides on each ring of said bicyclic heteroaryl, said heteroatoms are each independently O, S and N and said substituents are each independently:

- (1) hydrogen;
- (2) halo;
- (3) lower alkyl;
- (4) alkoxy;
- (5) alkylthio;
- (6) CN;
- (7) haloalkyl, preferably CF<sub>3</sub>;
- (8) N<sub>3</sub>;
- (9) -C(R<sup>5</sup>)(R<sup>6</sup>)-OD<sup>1</sup>; or
- (10) -C(R<sup>5</sup>)(R<sup>6</sup>)-O-lower alkyl;

- (r) K;
- (s) aryl;
- (t) arylalkyl;
- (u) cycloalkylalkyl;
- (v) -C(O)R<sup>11</sup>;
- (u) hydrogen;
- (v) arylalkenyl;
- (w) arylalkoxy;
- (x) alkoxy;
- (y) aryloxy;
- (z) cycloalkoxy;
- (aa) arylthio;
- (bb) alkylthio;
- (cc) arylalkylthio; or
- (dd) cycloalkylthio;

$R^3$  is:

- (a) hydrogen;
- (b) haloalkyl, preferably  $CF_3$ ;
- (c)  $CN$ ;
- (d) lower alkyl;
- (e)  $(C(R_e)(R_f))_p-U-V$ ;
- (f)  $K$ ;
- (g) unsubstituted or substituted:

- (1) lower alkyl  $Q$ ;
- (2) lower alkyl  $O$  lower alkyl  $Q$ ;
- (3) lower alkyl  $S$  lower alkyl  $Q$ ;
- (4) lower alkyl  $O$   $Q$ ;
- (5) lower alkyl  $S$   $Q$ ;
- (6) lower alkyl  $O$   $V$ ;
- (7) lower alkyl  $S$   $V$ ;
- (8) lower alkyl  $O$   $K$ ; or
- (9) lower alkyl  $S$   $K$ ;

wherein the substituent(s) reside on the lower alkyl group;

- \_\_\_\_\_ (h)  $Q$ ;
- \_\_\_\_\_ (i) alkylcarbonyl;
- \_\_\_\_\_ (j) arylcarbonyl;
- \_\_\_\_\_ (k) alkylarylcarbonyl;
- \_\_\_\_\_ (l) arylalkylcarbonyl;
- \_\_\_\_\_ (m) carboxylic ester;
- \_\_\_\_\_ (n) carboxamido;
- \_\_\_\_\_ (o) cycloalkyl;

(p) mono-, di- or tri-substituted phenyl or naphthyl, wherein the substituents are each independently:

- (1) hydrogen;

- ~~(2) halo;~~
- ~~(3) alkoxy;~~
- ~~(4) alkylthio;~~
- ~~(5) CN;~~
- ~~(6) haloalkyl, preferably CF<sub>3</sub>;~~
- ~~(7) lower alkyl;~~
- ~~(8) N<sub>3</sub>;~~
- ~~(9) CO<sub>2</sub>D<sup>+</sup>;~~
- ~~(10) CO<sub>2</sub> lower alkyl;~~
- ~~(11) (C(R<sup>5</sup>)(R<sup>6</sup>))<sub>z</sub>OD<sup>+</sup>;~~
- ~~(12) (C(R<sup>5</sup>)(R<sup>6</sup>))<sub>z</sub>O lower alkyl;~~
- ~~(13) lower alkyl CO<sub>2</sub>R<sup>5</sup>;~~
- ~~(14) OD<sup>+</sup>;~~
- ~~(15) haloalkoxy;~~
- ~~(16) amino;~~
- ~~(17) nitro; or~~
- ~~(18) alkylsulfinyl;~~

- ~~\_\_\_\_\_ (q) alkenyl;~~
- ~~\_\_\_\_\_ (r) alkynyl;~~
- ~~\_\_\_\_\_ (s) arylalkyl;~~
- ~~\_\_\_\_\_ (t) lower alkyl OD<sup>+</sup>;~~
- ~~\_\_\_\_\_ (u) alkoxyalkyl;~~
- ~~\_\_\_\_\_ (v) aminoalkyl;~~
- ~~\_\_\_\_\_ (w) lower alkyl CO<sub>2</sub>R<sup>10</sup>;~~
- ~~\_\_\_\_\_ (x) lower alkyl C(O)NR<sup>10</sup>(R<sup>10</sup>);~~
- ~~\_\_\_\_\_ (y) heterocyclicalkyl; or~~
- ~~\_\_\_\_\_ (z) heterocyclic ring C(O);~~

R<sup>4</sup>, R<sup>4'</sup>, R<sup>5</sup> and R<sup>5'</sup> are each independently:

- (a) hydrogen;

(b) amino;

(c) CN;

(d) lower alkyl;

(e) haloalkyl;

(f) alkoxy;

(g) alkylthio;

(h) Q;

(i) -O-Q;

(j) -S-Q;

(k) K;

(l) cycloalkoxy;

(m) cycloalkylthio;

(n) unsubstituted, mono-, or di-substituted phenyl or unsubstituted, mono-, or di-substituted benzyl, wherein the substituents are each independently:

(1) halo;

(2) lower alkyl;

(3) alkoxy;

(4) alkylthio;

(5) CN;

(6) haloalkyl, preferably CF<sub>3</sub>;

(7) N<sub>3</sub>;

(8) Q;

(9) nitro; or

(10) amino;

(o) unsubstituted, mono-, or di-substituted heteroaryl or unsubstituted, mono-, or di-substituted heteroarylmethyl, wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is S, O, or N, and, optionally, 1, 2, or 3 additional N atoms; or the heteroaryl is a monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, optionally, 1, 2, 3, or 4 additional N atoms; said substituents are each independently:

- (1) halo;
- (2) lower alkyl;
- (3) alkoxy;
- (4) alkylthio;
- (5) CN;
- (6) haloalkyl, preferably CF<sub>3</sub>;
- (7) N<sub>3</sub>;
- (8) -C(R<sup>6</sup>)(R<sup>7</sup>)-OD<sup>1</sup>;
- (9) -C(R<sup>6</sup>)(R<sup>7</sup>)-O-lower alkyl; or
- (10) alkylsulfinyl

(p) -CON(R<sup>8</sup>)(R<sup>8</sup>);

(q) -CH<sub>2</sub>OR<sup>8</sup>;

(r) -CH<sub>2</sub>OCN;

(s) unsubstituted or substituted:

- (1) lower alkyl-Q;
- (2) -O-lower alkyl-Q;
- (3) -S-lower alkyl-Q;
- (4) lower alkyl-O-lower alkyl-Q;
- (5) lower alkyl-S-lower alkyl-Q;
- (6) lower alkyl-O-Q;
- (7) lower alkyl-S-Q;
- (8) lower alkyl-O-K;
- (9) lower alkyl-S-K;
- (10) lower alkyl-O-V; or
- (11) lower alkyl-S-V;

wherein the substituent(s) resides on the lower alkyl;

(t) cycloalkyl;

(u) aryl;

(v) arylalkyl;

- (w) cycloalkylalkyl;
- (x) aryloxy;
- (y) arylalkoxy;
- (z) arylalkylthio;
- (aa) cycloalkylalkoxy;
- (bb) heterocycloalkyl;
- (cc) alkylsulfonyloxy;
- (dd) alkylsulfonyl;
- (ee) arylsulfonyl;
- (ff) arylsulfonyloxy;
- (gg)  $-C(O)R^{10}$ ;
- (hh) nitro;
- (ii) amino;
- (jj) aminoalkyl;
- (kk)  $-C(O)$ -alkyl-heterocyclic ring;
- (ll) halo;
- (mm) heterocyclic ring;
- (nn)  $-CO_2D^1$ ;
- (oo) carboxyl;
- (pp) amidyl; or
- (qq) alkoxyalkyl;

alternatively,  $R^4$  and  $R^5$  together with the carbons to which they are attached are:

- (a) cycloalkyl;
- (b) aryl; or
- (c) heterocyclic ring;

alternatively,  $R^4$  and  $R^{4'}$  or  $R^5$  and  $R^{5'}$  taken together with the carbon to which they are attached are:

- (a) cycloalkyl; or
- (b) heterocyclic ring;

alternatively,  $R^4$  and  $R^5$ ,  $R^{4'}$  and  $R^{5'}$ ,  $R^4$  and  $R^{5'}$ , or  $R^{4'}$  and  $R^5$  when substituents on adjacent carbon atoms taken together with the carbons to which they are attached are:

- (a) cycloalkyl;
- (b) heterocyclic ring; or
- (c) aryl;

$R^6$  and  $R^7$  are each independently:

- (a) hydrogen;
- (b) unsubstituted, mono- or di-substituted phenyl; unsubstituted, mono- or di-substituted benzyl; unsubstituted, mono- or di-substituted heteroaryl; mono- or di-substituted heteroarylmethyl, wherein said substituents are each independently:

- (1) halo;
- (2) lower alkyl;
- (3) alkoxy;
- (4) alkylthio;
- (5) CN;
- (6) haloalkyl, preferably  $CF_3$ ;
- (7)  $N_3$ ;
- (8)  $-C(R^{14})(R^{15})-OD^1$ ; or
- (9)  $-C(R^{14})(R^{15})-O$ -lower alkyl;

- (c) lower alkyl;
- (d)  $-CH_2OR^8$ ;
- (e) CN;
- (f)  $-CH_2CN$ ;
- (g) haloalkyl, preferably fluoroalkyl;
- (h)  $-CON(R^8)(R^8)$ ;
- (i) halo; or
- (j)  $-OR^8$ ;

$R^8$  is:

- (a) hydrogen;

(b) K; or

(c)  $R^9$ ;

alternatively,  $R^5$  and  $R^{5'}$ ,  $R^6$  and  $R^7$  or  $R^7$  and  $R^8$  together with the carbon to which they are attached form a saturated monocyclic ring of 3, 4, 5, 6 or 7 atoms; optionally containing up to two heteroatoms selected from oxygen,  $S(O)_0$  or  $NR_i$ ;

$R^9$  is:

(a) lower alkyl;

(b) lower alkyl- $CO_2D^1$ ;

(c) lower alkyl-NHD<sup>1</sup>;

(d) phenyl or mono-, di- or tri-substituted phenyl, wherein the substituents are each independently:

(1) halo;

(2) lower alkyl;

(3) alkoxy;

(4) alkylthio;

(5) lower alkyl- $CO_2D^1$ ;

(6) lower alkyl-NHD<sup>1</sup>;

(7) CN;

(8)  $CO_2D^1$ ; or

(9) haloalkyl, preferably fluoroalkyl;

(e) benzyl, mono-, di- or tri-substituted benzyl, wherein the substituents are each independently:

(1) halo;

(2) lower alkyl;

(3) alkoxy;

(4) alkylthio;

(5) lower alkyl- $CO_2D^1$ ;

(6) lower alkyl-NHD<sup>1</sup>;

(7) CN;



(8)  $-\text{CO}_2\text{D}^1$ ; or

(9) haloalkyl, preferably  $\text{CF}_3$ ;

(f) cycloalkyl;

(g) K; or

(h) benzoyl, mono-, di-, or trisubstituted benzoyl, wherein the substituents are each independently:

(1) halo;

(2) lower alkyl;

(3) alkoxy;

(4) alkylthio;

(5) lower alkyl- $\text{CO}_2\text{D}^1$ ;

(6) lower alkyl-NHD<sup>1</sup>;

(7) CN;

(8)  $-\text{CO}_2\text{D}^1$ ; or

(9) haloalkyl, preferably  $\text{CF}_3$ ;

$\text{R}^{10}$  and  $\text{R}^{10'}$  are each independently:

(a) hydrogen; or

(b)  $\text{R}^{11}$ ;

$\text{R}^{11}$  is:

(a) lower alkyl;

(b) cycloalkyl;

(c) unsubstituted, mono-, di- or tri-substituted phenyl or naphthyl, wherein the substituents are each independently:

(1) halo;

(2) alkoxy;

(3) alkylthio;

(4) CN;

(5) haloalkyl, preferably  $\text{CF}_3$ ;

(6) lower alkyl;

- (7)  $N_3$ ;
- (8)  $-CO_2D^1$ ;
- (9)  $-CO_2$ -lower alkyl;
- (10)  $-C(R^{12})(R^{13})-OD^1$ ;
- (11)  $-C(R^{12})(R^{13})-O$ -lower alkyl;
- (12) lower alkyl- $CO_2D^1$ ;
- (13) lower alkyl- $CO_2R^{12}$ ;
- (14) benzyloxy;
- (15)  $-O$ -(lower alkyl)- $CO_2D^1$ ;
- (16)  $-O$ -(lower alkyl)- $CO_2R^{12}$ ; or
- (17)  $-O$ -(lower alkyl)- $NR^{12}R^{13}$ ;

(d) unsubstituted, mono-, di- or tri-substituted heteroaryl, wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is S, O, or N, and, optionally, 1, 2, or 3 additional N atoms; or said heteroaryl is a monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, optionally 1, 2, or 3 additional N atoms, and wherein said substituents are each independently:

- (1) halo;
- (2) lower alkyl;
- (3) alkoxy;
- (4) alkylthio;
- (5) CN;
- (6) haloalkyl, preferably  $CF_3$ ;
- (7)  $N_3$ ;
- (8)  $-C(R^{12})(R^{13})-OD^1$ ; or
- (9)  $-C(R^{12})(R^{13})-O$ -lower alkyl;

(e) unsubstituted, mono- or di-substituted benzoheterocycle, wherein the benzoheterocycle is a 5, 6, or 7-membered ring which contains 1 or 2 heteroatoms independently selected from O, S, or N, and, optionally, a carbonyl group or a sulfonyl group, wherein said substituents are each independently:

- (1) halo;
- (2) lower alkyl;
- (3) alkoxy;
- (4) alkylthio;
- (5) CN;
- (6) haloalkyl, preferably CF<sub>3</sub>;
- (7) N<sub>3</sub>;
- (8) -C(R<sup>12</sup>)(R<sup>13</sup>)-OD<sup>1</sup>; or
- (9) -C(R<sup>12</sup>)(R<sup>13</sup>)-O-lower alkyl;

(f) unsubstituted, mono- or di-substituted benzocarbocycle, wherein the carbocycle is a 5, 6, or 7-membered ring which optionally contains a carbonyl group, wherein said substituents are each independently :

- (1) halo;
- (2) lower alkyl;
- (3) alkoxy;
- (4) alkylthio;
- (5) CN;
- (6) haloalkyl, preferably CF<sub>3</sub>;
- (7) N<sub>3</sub>;
- (8) -C(R<sup>12</sup>)(R<sup>13</sup>)-OD<sup>1</sup>; or
- (9) -C(R<sup>12</sup>)(R<sup>13</sup>)-O-lower alkyl;

(g) hydrogen; or

(h) K

R<sup>12</sup> and R<sup>13</sup> are each independently:

- (a) hydrogen;
- (b) lower alkyl; or
- (c) aryl; or

R<sup>12</sup> and R<sup>13</sup> together with the atom to which they are attached form a saturated monocyclic ring of 3, 4, 5, 6 or 7 atoms;

$R^{14}$  and  $R^{15}$  are each independently :

- (a) hydrogen; or
- (b) lower alkyl; or

$R^{14}$  and  $R^{15}$  together with the atom to which they are attached form a carbonyl, a thial, or a saturated monocyclic ring of 3, 4, 5, 6 or 7 atoms;

$D^1$  is:

- (a) hydrogen or
- (b) D;

D is:

- (a) V; or
- (b) K;

U is:

- (a) oxygen;
- (b) sulfur; or
- (c)  $-N(R_a)(R_i)-$ ;

V is:

- (a) -NO;
- (b) -NO<sub>2</sub>; or
- (c) hydrogen

K is  $-W_{aa}-E_b-(C(R_e)(R_f))_p-E_c-(C(R_e)(R_f))_x-W_d-(C(R_e)(R_f))_y-W_i-E_j-W_g-(C(R_e)(R_f))_z-U-V$ ;

wherein aa, b, c, d, g, i and j are each independently an integer from 0 to 3;

p, x, y and z are each independently an integer from 0 to 10;

W at each occurrence is independently:

- (a)  $-C(O)-$ ;
- (b)  $-C(S)-$ ;
- (c) -T-;
- (d)  $-(C(R_e)(R_f))_h-$ ;
- (e) alkyl;
- (f) aryl;

- (g) heterocyclic ring;
- (h) arylheterocyclic ring, or
- (i)  $-(\text{CH}_2\text{CH}_2\text{O})_q-$ ;

E at each occurrence is independently:

- (a) -T-;
- (b) alkyl;
- (c) aryl;
- (d)  $-(\text{C}(\text{R}_e)(\text{R}_f))_h-$ ;
- (e) heterocyclic ring;
- (f) arylheterocyclic ring; or
- (g)  $-(\text{CH}_2\text{CH}_2\text{O})_q-$ ;

h is an integer from 1 to 10;

q is an integer from 1 to 5;

$\text{R}_e$  and  $\text{R}_f$  are each independently:

- (a) hydrogen;
- (b) alkyl;
- (c) cycloalkoxy;
- (d) halogen;
- (e) hydroxy;
- (f) hydroxyalkyl;
- (g) alkoxyalkyl;
- (h) arylheterocyclic ring;
- (i) cycloalkylalkyl;
- (j) heterocyclicalkyl;
- (k) alkoxy;
- (l) haloalkoxy;
- (m) amino;
- (n) alkylamino;
- (o) dialkylamino;

- (p) arylamino;
- (q) diarylamino;
- (r) alkylarylamino;
- (s) alkoxyhaloalkyl;
- (t) haloalkoxy;
- (u) sulfonic acid;
- (v) alkylsulfonic acid;
- (w) arylsulfonic acid;
- (x) arylalkoxy;
- (y) alkylthio;
- (z) arylthio;
- (aa) cyano;
- (bb) aminoalkyl;
- (cc) aminoaryl;
- (dd) alkoxy;
- (ee) aryl;
- (ff) arylalkyl;
- (gg) carboxamido;
- (hh) alkylcarboxamido;
- (ii) arylcarboxamido;
- (jj) amidyl;
- (kk) carboxyl;
- (ll) carbamoyl;
- (mm) alkylcarboxylic acid;
- (nn) arylcarboxylic acid;
- (oo) alkylcarbonyl;
- (pp) arylcarbonyl;
- (qq) ester;
- (rr) carboxylic ester;

- (ss) alkylcarboxylic ester;
- (tt) arylcarboxylic ester;
- (uu) haloalkoxy;
- (vv) sulfonamido;
- (ww) alkylsulfonamido;
- (xx) arylsulfonamido;
- (yy) alkylsulfonyl,
- (zz) alkylsulfonyloxy,
- (aaa) arylsulfonyl,
- (bbb) arylsulphonyloxy
- (ccc) sulfonic ester;
- (ddd) carbamoyl;
- (eee) urea;
- (fff) nitro;
- (ggg) -U-V; or
- (hhh)  $-(C(R'_e)(R'_f))_k-U-V$  or

$R_e$  and  $R_f$  taken together are:

- (a) oxo;
- (b) thial;
- (c) oxime; or
- (d) hydrazone;

$R_e$  and  $R_f$  taken together with the carbon atom to which they are attached are:

- (a) heterocyclic ring;
- (b) cycloalkyl group; or
- (c) bridged cycloalkyl group;

$R'_e$  and  $R'_f$  are each independently selected from  $R_e$ ;

k is an integer from 1 to 3;

T at each occurrence is independently:

- (a) a covalent bond,

- (b) carbonyl,
- (c) an oxygen,
- (d)  $-S(O)_o-$ ; or
- (e)  $-N(R_a)(R_i)-$ ;

o is an integer from 0 to 2;

Q is:

- (a)  $-C(O)-U-D^1$ ;
- (b)  $-CO_2$ -lower alkyl;
- (c) tetrazolyl-5-yl;
- (d)  $-C(R^7)(R^8)(S-D^1)$ ;
- (e)  $-C(R^7)(R^8)(O-D^1)$ ; or
- (f)  $-C(R^7)(R^8)(O$ -lower alkyl);

$R_a$  is:

- (a) a lone pair of electron;
- (b) hydrogen; or
- (c) lower alkyl;

$R_i$  is:

- (a) hydrogen;
- (b) alkyl;
- (c) aryl;
- (d) alkylcarboxylic acid;
- (e) arylcarboxylic acid;
- (f) alkylcarboxylic ester;
- (g) arylcarboxylic ester;
- (h) alkylcarboxamido;
- (i) arylcarboxamido;
- (j) alkylsulfinyl;
- (k) alkylsulfonyl;
- (l) alkylsulfonyloxy,



- (m) arylsulfinyl;
- (n) arylsulfonyl;
- (o) arylsulphonyloxy;
- (p) sulfonamido;
- (q) carboxamido;
- (r) carboxylic ester;
- (s) aminoalkyl;
- (t) aminoaryl;
- (u)  $-\text{CH}_2-\text{C}(\text{U}-\text{V})(\text{R}_e)(\text{R}_f)$ ;
- (v) a bond to an adjacent atom creating a double bond to that atom; or
- (w)  $-(\text{N}_2\text{O}_2)^-\cdot\text{M}^+$ , wherein  $\text{M}^+$  is an organic or inorganic cation;

with the proviso that the compound of Formula (II) must contain at least one oxime group and/or hydrazone group.

60. (New) A composition comprising the compound of claim 59 and a pharmaceutically acceptable carrier.

61. (New) A method for treating or reducing inflammation, pain or fever in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 60.

62. (New) A method for treating a gastrointestinal disorder, or improving the gastrointestinal properties of a COX-2 inhibitor in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 60.

63. (New) The method of claim 62, wherein the gastrointestinal disorder is an inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, ulcerative colitis, a peptic ulcer, a stress ulcer, a bleeding ulcer, gastric hyperacidity, dyspepsia, gastroparesis, Zollinger-Ellison syndrome, gastroesophageal reflux disease, a bacterial infection, short-bowel (anastomosis) syndrome, or a hypersecretory state associated with systemic mastocytosis or basophilic leukemia and hyperhistaminemia.

64. (New) A method for facilitating wound healing in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 60.

65. (New) The method of claim 64, wherein the wound is an ulcer.

66. (New) A method for treating or reversing renal and/or respiratory toxicity in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 60.

67. (New) A method for treating a disorder resulting from elevated levels of COX-2 in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 60.

68. (New) The method of claim 67, wherein the disorder resulting from elevated levels of COX-2 is angiogenesis, arthritis, asthma, bronchitis, menstrual cramps, premature labor, tendinitis, bursitis, a skin-related condition, neoplasia, an inflammatory process in a disease, an ophthalmic disorder, pulmonary inflammation, a central nervous system disorder, allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome, atherosclerosis, a microbial infection, a cardiovascular disorder, a urinary disorder, a urological disorder, endothelial dysfunction, organ deterioration, tissue deterioration, or activation, adhesion and infiltration of neutrophils at the site of inflammation.

69. (New) The method of claim 10, wherein the neoplasia is a brain cancer, a bone cancer, an epithelial cell-derived neoplasia (epithelial carcinoma), a basal cell carcinoma, an adenocarcinoma, a gastrointestinal cancer, a lip cancer, a mouth cancer, an esophageal cancer, a small bowel cancer, a stomach cancer, a colon cancer, a liver cancer, a bladder cancer, a pancreas cancer, an ovary cancer, a cervical cancer, a lung cancer, a breast cancer, a skin cancer, a squamous cell cancer, a basal cell cancer, a prostate cancer, a renal cell carcinoma, a cancerous tumor, a growth, a polyp, an adenomatous polyp, a familial adenomatous polyposis or a fibrosis resulting from radiation therapy.

70. (New) The method of claim 68, wherein the central nervous system disorder is cortical dementia, Alzheimer's disease, vascular dementia, multi-infarct dementia, pre-senile

dementia, alcoholic dementia, senile dementia, or central nervous system damage resulting from stroke, ischemia or trauma.

71. (New) A method for inhibiting platelet aggregation in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 60.

72. (New) The composition of claim 60, further comprising at least one therapeutic agent.

73. (New) The composition of claim 72, wherein the therapeutic agent is a steroid, a nonsteroidal antiinflammatory compound, a 5-lipoxygenase (5-LO) inhibitor, a leukotriene B<sub>4</sub> receptor antagonist, a leukotriene A<sub>4</sub> hydrolase inhibitor, a 5-HT agonist, a 3-hydroxy-3-methylglutaryl coenzyme A inhibitor, a H<sub>2</sub> antagonist, an antineoplastic agent, an antiplatelet agent, a thrombin inhibitor, a thromboxane inhibitor, a decongestant, a diuretic, a sedating or non-sedating anti-histamine, an inducible nitric oxide synthase inhibitor, an opioid, an analgesic, a *Helicobacter pylori* inhibitor, a proton pump inhibitor, an isoprostane inhibitor, or a mixture of two or more thereof.

74. (New) The composition of claim 73, wherein the nonsteroidal antiinflammatory compound is acetaminophen, aspirin, diclofenac, ibuprofen, ketoprofen or naproxen.

75. (New) A method for treating or reducing inflammation, pain or fever in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 72.

76. (New) A method for treating a gastrointestinal disorder, or improving the gastrointestinal properties of a COX-2 inhibitor in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 72.

77. (New) The method of claim 76, wherein the gastrointestinal disorder is an inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, ulcerative colitis, a peptic ulcer, a stress ulcer, a bleeding ulcer, gastric hyperacidity, dyspepsia, gastroparesis, Zollinger-Ellison syndrome, gastroesophageal reflux disease, a bacterial infection, short-bowel (anastomosis) syndrome, or a hypersecretory state associated with systemic mastocytosis or basophilic leukemia and hyperhistaminemia.

78. (New) A method for facilitating wound healing in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 72.

79. (New) The method of claim 78, wherein the wound is an ulcer.

80. (New) A method for treating or reversing renal and/or respiratory toxicity in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 72.

81. (New) A method for treating a disorder resulting from elevated levels of COX-2 in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 72.

82. (New) The method of claim 81, wherein the disorder resulting from elevated levels of COX-2 is angiogenesis, arthritis, asthma, bronchitis, menstrual cramps, premature labor, tendinitis, bursitis, a skin-related condition, neoplasia, an inflammatory process in a disease, an ophthalmic disorder, pulmonary inflammation, a central nervous system disorder, allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome, atherosclerosis, a microbial infection, a cardiovascular disorder, a urinary disorder, a urological disorder, endothelial dysfunction, organ deterioration, tissue deterioration, or activation, adhesion and infiltration of neutrophils at the site of inflammation.

83. (New) The method of claim 82, wherein the neoplasia is a brain cancer, a bone cancer, an epithelial cell-derived neoplasia (epithelial carcinoma), a basal cell carcinoma, an adenocarcinoma, a gastrointestinal cancer, a lip cancer, a mouth cancer, an esophageal cancer, a small bowel cancer, a stomach cancer, a colon cancer, a liver cancer, a bladder cancer, a pancreas cancer, an ovary cancer, a cervical cancer, a lung cancer, a breast cancer, a skin cancer, a squamous cell cancer, a basal cell cancer, a prostate cancer, a renal cell carcinoma, a cancerous tumor, a growth, a polyp, an adenomatous polyp, a familial adenomatous polyposis or a fibrosis resulting from radiation therapy.

84. (New) The method of claim 82, wherein the central nervous system disorder is cortical dementia, Alzheimer's disease, vascular dementia, multi-infarct dementia, pre-senile

dementia, alcoholic dementia, senile dementia, or central nervous system damage resulting from stroke, ischemia or trauma.

85. (New) A method for inhibiting platelet aggregation in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 72.

86. (New) A composition comprising at least one compound of claim 59 and at least one compound that donates, transfers or releases nitric oxide, or induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, or is a substrate for nitric oxide synthase.

87. (New) The composition of claim 86, further comprising a pharmaceutically acceptable carrier.

88. (New) The composition of claim 86, wherein the compound that donates, transfers, or releases nitric oxide, or induces the production of endogenous nitric oxide or endothelium-derived relaxing factor or is a substrate for nitric oxide synthase is an S-nitrosothiol.

89. (New) The composition of claim 88, wherein the S-nitrosothiol is S-nitroso-N-acetylcysteine, S-nitroso-captopril, S-nitroso-N-acetylpenicillamine, S-nitroso-homocysteine, S-nitroso-cysteine, S-nitroso-glutathione, or S-nitroso-cysteinyl-glycine.

90. (New) The composition of claim 88, wherein the S-nitrosothiol is:

- (i)  $\text{HS}(\text{C}(\text{R}_e)(\text{R}_f))_m\text{SNO}$ ;
- (ii)  $\text{ONS}(\text{C}(\text{R}_e)(\text{R}_f))_m\text{R}_e$ ; or
- (iii)  $\text{H}_2\text{N}-\text{CH}(\text{CO}_2\text{H})-(\text{CH}_2)_m-\text{C}(\text{O})\text{NH}-\text{CH}(\text{CH}_2\text{SNO})-\text{C}(\text{O})\text{NH}-\text{CH}_2-\text{CO}_2\text{H}$ ;

wherein m is an integer from 2 to 20;  $\text{R}_e$  and  $\text{R}_f$  are each independently a hydrogen, an alkyl, a cycloalkoxy, a halogen, a hydroxy, an hydroxyalkyl, an alkoxyalkyl, an arylheterocyclic ring, a cycloalkylalkyl, a heterocyclicalkyl, an alkoxy, a haloalkoxy, an amino, an alkylamino, a dialkylamino, an arylamino, a diarylamino, an alkylaryl amino, an alkoxyhaloalkyl, a haloalkoxy, a sulfonic acid, a sulfonic ester, an alkylsulfonic acid, an arylsulfonic acid, an arylalkoxy, an alkylthio, an arylthio, a cyano, an aminoalkyl, an aminoaryl, an aryl, an arylalkyl, a carboxamido, an alkylcarboxamido, an arylcarboxamido, an amidyl, a carboxyl, a carbamoyl, an alkylcarboxylic acid, an arylcarboxylic acid, an alkylcarbonyl, an arylcarbonyl, an ester, a carboxylic ester, an

alkylcarboxylic ester, an arylcarboxylic ester, a haloalkoxy, a sulfonamido, an alkylsulfonamido, an arylsulfonamido, an alkylsulfonyl, an alkylsulfonyloxy, an arylsulfonyl, an arylsulfonyloxy, a urea, a nitro, -T-Q'-, or  $-(C(R_g)(R_h))_k-T-Q'$  or  $R_e$  and  $R_f$  taken together are an oxo, a methanthial, a heterocyclic ring, a cycloalkyl group, an oxime, a hydrazone or a bridged cycloalkyl group;  $Q'$  is -NO or -NO<sub>2</sub>; and T is independently a covalent bond, a carbonyl, an oxygen, -S(O)<sub>o</sub>- or -N(R<sub>a</sub>)R<sub>i</sub>-, wherein o is an integer from 0 to 2, R<sub>a</sub> is a lone pair of electrons, a hydrogen or an alkyl group; R<sub>i</sub> is a hydrogen, an alkyl, an aryl, an alkylcarboxylic acid, an arylcarboxylic acid, an alkylcarboxylic ester, an arylcarboxylic ester, an alkylcarboxamido, an arylcarboxamido, an alkylsulfinyl, an alkylsulfonyl, an alkylsulfonyloxy, an arylsulfinyl, an arylsulfonyloxy, an arylsulfonyl, a sulfonamido, a carboxamido, a carboxylic ester, an aminoalkyl, an aminoaryl, -CH<sub>2</sub>-C(T-Q')(R<sub>g</sub>)(R<sub>h</sub>), or  $-(N_2O_2)^- \cdot M^+$ , wherein M<sup>+</sup> is an organic or inorganic cation; with the proviso that when R<sub>i</sub> is -CH<sub>2</sub>-C(T-Q')(R<sub>g</sub>)(R<sub>h</sub>) or  $-(N_2O_2)^- \cdot M^+$ ; then "-T-Q'" can be a hydrogen, an alkyl group, an alkoxyalkyl group, an aminoalkyl group, a hydroxy group or an aryl group; and R<sub>g</sub> and R<sub>h</sub> at each occurrence are independently R<sub>e</sub>.

91. (New) The composition of claim 86, wherein the compound that donates, transfers, or releases nitric oxide, or induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, or is a substrate for nitric oxide synthase is L-arginine, L-homoarginine, N-hydroxy-L-arginine, nitrosated L-arginine, nitrosylated L-arginine, nitrosated N-hydroxy-L-arginine, nitrosylated N-hydroxy-L-arginine, nitrosated L-homoarginine, nitrosylated L-homoarginine), citrulline, ornithine, glutamine, lysine, an arginase inhibitor or a nitric oxide mediator.

92. (New) The composition of claim 86, wherein the compound that donates, transfers, or releases nitric oxide, or induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, or is a substrate for nitric oxide synthase is:

- (i) a compound that comprises at least one ON-O- or ON-N- group;
- (ii) a compound that comprises at least one O<sub>2</sub>N-O-, O<sub>2</sub>N-N- or O<sub>2</sub>N-S- or group;
- (iii) a N-oxo-N-nitrosoamine having the formula: R<sup>1''</sup>R<sup>2''</sup>N-N(O-M<sup>+</sup>)-NO, wherein R<sup>1''</sup> and R<sup>2''</sup> are each independently a polypeptide, an amino acid, a sugar, an oligonucleotide, a

straight or branched, saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted hydrocarbon, or a heterocyclic group, and  $M^+$  is an organic or inorganic cation.

93. (New) The composition of claim 92, wherein the compound comprising at least one ON-O- or ON-N- group is an ON-O-polypeptide, an ON-N-polypeptide, an ON-O-amino acid, an ON-N-amino acid, an ON-O-sugar, an ON-N-sugar, an ON-O-oligonucleotide, an ON-N-oligonucleotide, a straight or branched, saturated or unsaturated, substituted or unsubstituted, aliphatic or aromatic ON-O-hydrocarbon, a straight or branched, saturated or unsaturated, substituted or unsubstituted, aliphatic or aromatic ON-N-hydrocarbon, an ON-O-heterocyclic compound or an ON-N-heterocyclic compound.

94. (New) The composition of claim 92, wherein compound comprising at least one  $O_2N$ -O-,  $O_2N$ -N- or  $O_2N$ -S- group is an  $O_2N$ -O-polypeptide, an  $O_2N$ -N-polypeptide, an  $O_2N$ -S-polypeptide, an  $O_2N$ -O-amino acid,  $O_2N$ -N-amino acid,  $O_2N$ -S-amino acid, an  $O_2N$ -O-sugar, an  $O_2N$ -N-sugar,  $O_2N$ -S-sugar, an  $O_2N$ -O-oligonucleotide, an  $O_2N$ -N-oligonucleotide, an  $O_2N$ -S-oligonucleotide, a straight or branched, saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted  $O_2N$ -O-hydrocarbon, a straight or branched, saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted  $O_2N$ -N-hydrocarbon, a straight or branched, saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted  $O_2N$ -S-hydrocarbon, an  $O_2N$ -O-heterocyclic compound, an  $O_2N$ -N-heterocyclic compound or an  $O_2N$ -S-heterocyclic compound.

95. (New) The composition of claim 86, further comprising at least one therapeutic agent.

96. (New) The composition of claim 95, wherein the therapeutic agent is a steroid, a nonsteroidal antiinflammatory compound, a 5-lipoxygenase (5-LO) inhibitor, a leukotriene  $B_4$  receptor antagonist, a leukotriene  $A_4$  hydrolase inhibitor, a 5-HT agonist, a HMG CoA inhibitor, a  $H_2$  antagonist, an antineoplastic agent, an antiplatelet agent, a thrombin inhibitor, a thromboxane inhibitor, a decongestant, a diuretic, a sedating or non-sedating anti-histamine, an inducible nitric oxide synthase inhibitor, an opioid, an analgesic, a *Helicobacter pylori* inhibitor, a proton pump inhibitor, an isoprostane inhibitor, or a mixture of two or more thereof.

97. (New) The composition of claim 96, wherein the nonsteroidal antiinflammatory compound is acetaminophen, aspirin, diclofenac, ibuprofen, ketoprofen or naproxen.

98. (New) A method for treating or reducing inflammation, pain or fever in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 87 or 95.

99. (New) A method for treating a gastrointestinal disorder, or improving the gastrointestinal properties of a COX-2 inhibitor in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 87 or 95.

100. (New) The method of claim 99, wherein the gastrointestinal disorder is an inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, ulcerative colitis, a peptic ulcer, a stress ulcer, a bleeding ulcer, gastric hyperacidity, dyspepsia, gastroparesis, Zollinger-Ellison syndrome, gastroesophageal reflux disease, a bacterial infection, short-bowel (anastomosis) syndrome, or a hypersecretory state associated with systemic mastocytosis or basophilic leukemia and hyperhistaminemia.

101. (New) A method for facilitating wound healing in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 87 or 95.

102. (New) The method of claim 101, wherein the wound is an ulcer.

103. (New) A method for treating or reversing renal and/or respiratory toxicity in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 87 or 95.

104. (New) A method for treating a disorder resulting from elevated levels of COX-2 in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 87 or 95.

105. (New) The method of claim 104, wherein the disorder resulting from elevated levels of COX-2 is angiogenesis, arthritis, asthma, bronchitis, menstrual cramps, premature labor, tendinitis, bursitis, a skin-related condition, neoplasia, an inflammatory process in a disease, an ophthalmic disorder, pulmonary inflammation, a central nervous system disorder, allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome, atherosclerosis, a microbial infection, a cardiovascular disorder, a urinary disorder, a urological disorder,



endothelial dysfunction, organ deterioration, tissue deterioration, or activation, adhesion and infiltration of neutrophils at the site of inflammation.

106. (New) The method of claim 105, wherein the neoplasia is a brain cancer, a bone cancer, an epithelial cell-derived neoplasia (epithelial carcinoma), a basal cell carcinoma, an adenocarcinoma, a gastrointestinal cancer, a lip cancer, a mouth cancer, an esophageal cancer, a small bowel cancer, a stomach cancer, a colon cancer, a liver cancer, a bladder cancer, a pancreas cancer, an ovary cancer, a cervical cancer, a lung cancer, a breast cancer, a skin cancer, a squamous cell cancer, a basal cell cancer, a prostate cancer, a renal cell carcinoma, a cancerous tumor, a growth, a polyp, an adenomatous polyp, a familial adenomatous polyposis or a fibrosis resulting from radiation therapy.

107. (New) The method of claim 105, wherein the central nervous system disorder is cortical dementia, Alzheimer's disease, vascular dementia, multi-infarct dementia, pre-senile dementia, alcoholic dementia, senile dementia, or central nervous system damage resulting from stroke, ischemia or trauma.

108. (New) A method for inhibiting platelet aggregation in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 87 or 95.

109. (New) A kit comprising at least one compound of claim 59.

110. (New) The kit of claim 109, further comprising (i) at least one compound that donates, transfers or releases nitric oxide, induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, or is a substrate for nitric oxide synthase; (ii) at least one therapeutic agent; or (iii) at least one compound that donates, transfers or releases nitric oxide, induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, or is a substrate for nitric oxide synthase and at least one therapeutic agent.

111. (New) The kit of claim 110, wherein the at least one compound that donates, transfers or releases nitric oxide, induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, or is a substrate for nitric oxide synthase; the at least one therapeutic agent; or the at least one compound that donates, transfers or releases nitric oxide, induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, or is a

substrate for nitric oxide synthase and at least one therapeutic agent; are in the form of separate components in the kit.

112. (New) A kit comprising the composition of claim 72, 87 or 95.

113. (New) A compound selected from the group consisting of :

1-(3-(1-(hydroxyimino)-4-(nitrooxy)butyl)-1-phenylpyrazol-5-yl)-4-(methylsulfonyl)benzene;  
1-(1-cyclohexyl-3-(1-(hydroxyimino)-4-(nitrooxy)butyl)pyrazol-5-yl)-4-(methylsulfonyl)  
benzene; 1-(3-(2-aza-2-methoxy-1-(3-(nitrooxy)propyl)vinyl)-1-cyclohexylpyrazol-5-yl)-4-(  
methylsulfonyl)benzene; 4-(3-(1-(hydroxyimino)-5-(nitrooxy)butyl)-4-(4-(  
methylsulfonyl)phenyl)-pyrazolyl) benzenecarbonitrile; 1-(1-cyclohexyl-3-(1-(hydroximino)-6-(  
nitrooxy)hexyl)-pyrazol-5-yl)-4-(methylsulfonyl) benzene; *tert*-butyl 2-((1E)-2-{1-cyclohexyl-5-[  
4-(methylsulfonyl)phenyl]pyrazol-3-yl}-5-(nitrooxy)-1-azapent-1-enyloxy)acetate; or a  
pharmaceutically acceptable salt thereof.

114. (New) A composition comprising at least one compound of claim 113 and a pharmaceutically acceptable carrier.

115. (New) The composition of claim 114, further comprising (i) at least one compound that donates, transfers or releases nitric oxide, induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, or is a substrate for nitric oxide synthase; (ii) at least one therapeutic agent; or (iii) at least one compound that donates, transfers or releases nitric oxide, induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, or is a substrate for nitric oxide synthase and at least one therapeutic agent.

116. (New) A kit comprising at least one compound of claim 113.